Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eltrombopag plus azacitidine for thrombocytopenia in higher-risk myelodysplastic syndromes
RBR-4m42nqPhase 3Recruiting
- Sponsor
- GSK
- Start
- May 2014
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in myelodysplastic syndrome (MDS) comparing Eltrombopag + azacitidine with Placebo + azacitidine (2 arms). Started May 2014; status: recruiting.
02
Drugs
eltrombopagazacitidine
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on RBR-4m42nq.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on RBR-4m42nq.